Clinical Trials Logo

Malignant Gliomas clinical trials

View clinical trials related to Malignant Gliomas.

Filter by:

NCT ID: NCT00271609 Completed - Malignant Gliomas Clinical Trials

Bevacizumab for Recurrent Malignant Glioma

Start date: December 2005
Phase: Phase 2
Study type: Interventional

Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. Inhibiting the formation of these blood vessels may slow or stop disease progression by diminishing the supply of life-sustaining nutrients and oxygen the blood delivers to the tumor. Bevacizumab is approved for treating colorectal cancer and has shown activity against brain tumor cells in laboratory and animal tests. Objectives: To examine the safety and side effects of bevacizumab in patients with recurrent brain tumors. To determine the anti-tumor activity of bevacizumab in patients with recurrent brain tumors. Eligibility: Patients 18 years of age and older with a brain tumor that continues to grow after receiving standard treatments. Design: Patients complete the following procedures during the study: - Infusions of bevacizumab through a vein once every 2 weeks in 4-week treatment cycles. - Positron emission tomography (PET) scan before the first dose of bevacizumab, at the end of the first treatment cycle, and as needed after that. - Magnetic resonance imaging (MRI) scan before the first dose of bevacizumab, within 48-96 hours after the first dose of bevacizumab in the first treatment cycle, and then every 4 weeks. One tube of blood for research is collected at the time of each MRI scan to look at specific cells. - Physical and neurological examinations every 2 weeks for the first treatment cycle and then every 4 weeks. - Quality-of-life questionnaires every 4 weeks.

NCT ID: NCT00165477 Completed - Glioblastoma Clinical Trials

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Start date: September 2005
Phase: Phase 2
Study type: Interventional

- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.

NCT ID: NCT00074646 Completed - Glioblastoma Clinical Trials

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Start date: December 2003
Phase: Phase 1
Study type: Interventional

Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas